$AVTX
Avalo Therapeutics, Inc. Stock $avtx

$avtx Overview Financials Valuation SEC Filings Company Website

2022 Q2 Form 10-Q Financial Statement

#000162828022012436 Filed on May 05, 2022

Income Statement

Concept	2022 Q2	2022 Q1	2021 Q1
Revenue	$1.033M	$1.173M	$473.0K
YoY Change	-69.21%	147.99%	-82.82%
Cost Of Revenue	$1.567M	$720.0K	$77.00K
YoY Change	1787.95%	835.06%	16.67%
Gross Profit	-$534.0K	$453.0K	$396.0K
YoY Change	-116.32%	14.39%	-85.27%
Gross Profit Margin	-51.69%	38.62%	83.72%
Selling, General & Admin	$2.784M	$11.68M	$5.346M
YoY Change	-62.4%	118.56%	59.44%
% of Gross Profit		2579.25%	1350.0%
Research & Development	$8.510M	$9.584M	$2.500M
YoY Change	-32.29%	283.36%	-47.57%
% of Gross Profit		2115.67%	631.31%
Depreciation & Amortization	$30.00K	$67.00K	$451.0K
YoY Change	-93.42%	-85.14%	-0.44%
% of Gross Profit		14.79%	113.89%
Operating Expenses	$11.29M	$21.27M	$7.846M
YoY Change	-43.45%	171.07%	-3.39%
Operating Profit	-$11.83M	-$20.85M	-$30.58M
YoY Change	-30.95%	-31.81%	-2.65%
Interest Expense	-$1.154M	-$1.169M	$17.00K
YoY Change	382.85%	-6976.47%	70.0%
% of Operating Profit
Other Income/Expense, Net	-$1.154M	-$1.189M	$17.00K
YoY Change	372.95%	-7094.12%	-99.76%
Pretax Income	-$12.98M	-$22.04M	-$30.56M
YoY Change	-25.27%	-27.88%	25.71%
Income Tax	$5.000K	$9.000K	$11.00K
% Of Pretax Income
Net Earnings	-$12.99M	-$22.10M	-$30.68M
YoY Change	-24.07%	-27.97%	45.29%
Net Earnings / Revenue	-1257.21%	-1884.06%	-6486.26%
Basic Earnings Per Share	-$1.38	-$2.35
Diluted Earnings Per Share	-$1.381M	-$2.346M	-$4.157M
COMMON SHARES
Basic Shares Outstanding	112.8M shares	112.8M shares	89.10M shares
Diluted Shares Outstanding	9.401M shares	9.400M shares

Balance Sheet

Concept	2022 Q2	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$11.25M	$38.47M	$38.29M
YoY Change	-72.18%	0.46%	87.98%
Cash & Equivalents	$11.20M	$38.50M	$38.29M
Short-Term Investments
Other Short-Term Assets	$1.899M	$2.782M	$2.618M
YoY Change	6.03%	6.26%	211.67%
Inventory	$23.00K	$25.00K	$0.00
Prepaid Expenses
Receivables	$544.0K	$938.0K	$3.130M
Other Receivables	$1.306M	$1.445M	$2.056M
Total Short-Term Assets	$15.02M	$43.66M	$46.10M
YoY Change	-68.29%	-5.29%	80.87%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.567M	$2.604M	$1.530M
YoY Change	79.39%	70.2%	7.99%
Goodwill	$14.41M	$14.41M	$14.41M
YoY Change	0.0%	0.0%	0.0%
Intangibles	$0.00	$0.00	$1.161M
YoY Change	-100.0%	-100.0%	-56.93%
Long-Term Investments
YoY Change
Other Assets	$227.0K	$1.227M	$149.0K
YoY Change	52.35%	723.49%	35.45%
Total Long-Term Assets	$17.20M	$18.24M	$17.25M
YoY Change	2.88%	5.75%	-7.43%
TOTAL ASSETS
Total Short-Term Assets	$15.02M	$43.66M	$46.10M
Total Long-Term Assets	$17.20M	$18.24M	$17.25M
Total Assets	$32.22M	$61.90M	$63.35M
YoY Change	-49.72%	-2.28%	43.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.164M	$3.757M	$11.91M
YoY Change	-45.42%	-68.46%	337.01%
Accrued Expenses	$12.95M	$13.70M	$14.24M
YoY Change	-26.47%	-3.81%	130.02%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$15.40M	$17.89M	$26.36M
YoY Change	-28.97%	-32.12%	71.95%
LONG-TERM LIABILITIES
Long-Term Debt	$18.71M	$33.18M	$0.00
YoY Change	9.16%
Other Long-Term Liabilities	$1.939M	$2.358M	$1.719M
YoY Change	24.45%	37.17%	57.09%
Total Long-Term Liabilities	$1.939M	$2.358M	$1.719M
YoY Change	24.45%	37.17%	57.09%
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.40M	$17.89M	$26.36M
Total Long-Term Liabilities	$1.939M	$2.358M	$1.719M
Total Liabilities	$38.18M	$55.56M	$30.19M
YoY Change	-10.17%	84.02%	62.92%
SHAREHOLDERS EQUITY
Retained Earnings	-$297.2M	-$284.2M	-$208.5M
YoY Change	31.74%	36.31%	53.98%
Common Stock	$9.000K	$113.0K	$89.00K
YoY Change	-90.63%	26.97%	49.43%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$5.951M	$6.342M	$33.16M
YoY Change
Total Liabilities & Shareholders Equity	$32.22M	$61.90M	$63.35M
YoY Change	-49.72%	-2.28%	43.58%

Cashflow Statement

Concept	2022 Q2	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	-$12.99M	-$22.10M	-$30.68M
YoY Change	-24.07%	-27.97%	45.29%
Depreciation, Depletion And Amortization	$30.00K	$67.00K	$451.0K
YoY Change	-93.42%	-85.14%	-0.44%
Cash From Operating Activities	-$12.47M	-$16.10M	-$18.32M
YoY Change	-35.01%	-12.1%	219.15%
INVESTING ACTIVITIES
Capital Expenditures	-$56.00K	$0.00	$21.00K
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$56.00K	$0.00	-$21.00K
YoY Change		-100.0%	-98.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-14.78M	$0.00	$37.83M
YoY Change	-169.66%	-100.0%	315.75%
NET CHANGE
Cash From Operating Activities	-12.47M	-$16.10M	-$18.32M
Cash From Investing Activities	-56.00K	$0.00	-$21.00K
Cash From Financing Activities	-14.78M	$0.00	$37.83M
Net Change In Cash	-27.31M	-$16.07M	$19.49M
YoY Change	-1444.51%	-182.45%	824.48%
FREE CASH FLOW
Cash From Operating Activities	-$12.47M	-$16.10M	-$18.32M
Capital Expenditures	-$56.00K	$0.00	$21.00K
Free Cash Flow	-$12.41M	-$16.10M	-$18.34M
YoY Change	-35.3%	-12.2%	219.52%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001534120
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	avtx	Stockholders Equity Note Preferred Stock Conversion Ratio StockholdersEquityNotePreferredStockConversionRatio	0.20
CY2022Q1	avtx	Stockholders Equity Note Preferred Stock Conversion Ratio StockholdersEquityNotePreferredStockConversionRatio	0.20
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://www.avalotherapeutics.com/20220331#PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://www.avalotherapeutics.com/20220331#PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesAndOtherLiabilities
CY2022Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesAndOtherLiabilities
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	001-37590
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	AVALO THERAPEUTICS, INC.
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-0705648
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	540 Gaither Road, Suite 400
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Rockville
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20850
CY2022Q1	dei	City Area Code CityAreaCode	410
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	522-8707
CY2022Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
CY2022Q1	dei	Trading Symbol TradingSymbol	AVTX
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	112794203	shares
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38469000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54585000	USD
CY2022Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	938000	USD
CY2022Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1445000	USD
CY2021Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	3739000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	25000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2372000	USD
CY2021Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	1060000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	38000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2682000	USD
CY2022Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	100000	USD
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	51000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	43659000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	61845000	USD
CY2022Q1	avtx	Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	2604000	USD
CY2021Q4	avtx	Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	2695000	USD
CY2022Q1	us-gaap	Disposal Group Including Discontinued Operation Other Noncurrent Assets DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets	1000000	USD
CY2021Q4	us-gaap	Disposal Group Including Discontinued Operation Other Noncurrent Assets DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets	1000000	USD
CY2022Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	0	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	38000	USD
CY2022Q1	us-gaap	Goodwill Goodwill	14409000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	14409000	USD
CY2022Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	227000	USD
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	227000	USD
CY2022Q1	us-gaap	Assets Assets	61899000	USD
CY2021Q4	us-gaap	Assets Assets	80214000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	3757000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3369000	USD
CY2022Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	14136000	USD
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	16519000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	17893000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19888000	USD
CY2022Q1	us-gaap	Notes Payable NotesPayable	33183000	USD
CY2021Q4	us-gaap	Notes Payable NotesPayable	32833000	USD
CY2022Q1	us-gaap	Accrued Royalties Current And Noncurrent AccruedRoyaltiesCurrentAndNoncurrent	2000000	USD
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	113000	USD
CY2021Q4	us-gaap	Accrued Royalties Current And Noncurrent AccruedRoyaltiesCurrentAndNoncurrent	2000000	USD
CY2022Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	122000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	113000	USD
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2358000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2298000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	55556000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	57132000	USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	112794203	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	112794203	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	112794203	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	112794203	shares
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	290447000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	285135000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	23082000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	113000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-284217000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-262166000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	6343000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	61899000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	80214000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1173000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	473000	USD
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	720000	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	77000	USD
CY2022Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	9584000	USD
CY2021Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	25206000	USD
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9756000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4911000	USD
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1928000	USD
CY2021Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	435000	USD
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	38000	USD
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	424000	USD
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	22026000	USD
CY2021Q1	us-gaap	Costs And Expenses CostsAndExpenses	31053000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-20853000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-30580000	USD
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-20000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2022Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-1169000	USD
CY2021Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	17000	USD
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1189000	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	17000	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-22042000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1448000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-30680000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-30563000	USD
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	11000	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-22051000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-30574000	USD
CY2022Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	USD
CY2021Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-106000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-22051000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-30680000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	23082000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	5312000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-22051000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	6343000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	24562000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	37653000	USD
CY2021Q1	avtx	Stock Issued During Period Value Stock Options And Warrants Exercised StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised	172000	USD
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	67000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1448000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	33155000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-22051000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-30680000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	451000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	5312000	USD
CY2022Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	350000	USD
CY2021Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
CY2022Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	9000	USD
CY2021Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	21000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-123000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	953000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-2294000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-152000	USD
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-13000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	388000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	9339000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-2287000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-3000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	310000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-195000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	1724000	USD
CY2022Q1	avtx	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	25000	USD
CY2021Q1	avtx	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-16000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16067000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18316000	USD
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	21000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-21000	USD
CY2022Q1	avtx	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	0	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	37825000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-16067000	USD
CY2021Q1	avtx	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	37653000	USD
CY2022Q1	avtx	Proceeds From Option Or Warrant Exercises ProceedsFromOptionOrWarrantExercises	0	USD
CY2021Q1	avtx	Proceeds From Option Or Warrant Exercises ProceedsFromOptionOrWarrantExercises	172000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	19488000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	54863000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19106000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38796000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38594000	USD
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	831000	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38469000	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38292000	USD
CY2022Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	100000	USD
CY2021Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	153000	USD
CY2022Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	227000	USD
CY2021Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	149000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38796000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38594000	USD
CY2022Q1	us-gaap	Nature Of Operations NatureOfOperations	Business <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Avalo Therapeutics, Inc. (the “Company” or “Avalo”) is a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology and rare genetic diseases. The Company has built a diverse portfolio of innovative therapies to deliver meaningful medical impact for patients in urgent need. Avalo’s clinical candidates commonly have a proven mechanistic rationale, biomarkers and/or an established proof-of-concept to expedite and increase the probability of success. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Avalo was incorporated in Delaware and commenced operation in 2011, and completed its initial public offering in October 2015. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In order to meet its cash flow needs, the Company applies a disciplined decision-making methodology as it evaluates the optimal allocation of the Company’s resources between investing in the Company’s existing pipeline assets and acquisitions or in-licensing of new assets. As of March 31, 2022, Avalo had $38.5 million in cash and cash equivalents. For the three months ended March 31, 2022, Avalo generated a net loss of $22.1 million and negative cash flows from operations of $16.1 million. As of March 31, 2022, Avalo had an accumulated deficit of $284.2 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern; however, losses are expected to continue as the Company continues to invest in its research and development pipeline assets. The Company will require additional financing to fund its operations and to continue to execute its business strategy at least one year after the date the condensed consolidated financial statements included herein were issued. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To mitigate these conditions and to meet the Company’s capital requirements, management plans to use its current cash on hand along with some combination of the following: (i) dilutive and/or non-dilutive financings, (ii) federal and/or private grants, (iii) other out-licensing or strategic alliances/collaborations of its current pipeline assets, and (iv) out-licensing or sale of its non-core assets. If the Company raises additional funds through collaborations, strategic alliances or licensing arrangements with third parties, the Company might have to relinquish valuable rights to its technologies, future revenue streams, research programs or product candidates. Subject to limited exceptions, our venture debt financing agreement prohibits us from incurring certain additional indebtedness, making certain asset dispositions, and entering into certain mergers, acquisitions or other business combination transactions without prior consent of the Lenders. Additionally, our venture debt financing agreement contains certain covenants and certain other specified events that could result in an event of default, which if not cured or waived, could result in the immediate acceleration of all or a substantial portion of the Notes (as defined in Note 9). As of the filing date of this Quarterly Report on Form 10-Q, the Company was not aware of any breach of covenants or occurrence of material adverse change, nor had it received any notice of event of default from the Lenders (refer to Note 9 for more information).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company requires but is unable to obtain additional funding, the Company may be forced to make reductions in spending, delay, suspend, reduce or eliminate some or all of its planned research and development programs, or liquidate assets where possible. Due to the uncertainty regarding future financing and other potential options to raise additional funds, management has concluded that substantial doubt exists with respect to the Company’s ability to continue as a going concern within one year after the date that the financial statements in this Quarterly Report on Form 10-Q were issued. </span></div>Over the long term, the Company’s ultimate ability to achieve and maintain profitability will depend on, among other things, the development, regulatory approval, and commercialization of its pipeline assets, and the potential receipt and sale of any priority review vouchers it receives.
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38500000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-22100000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16100000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-284200000	USD
CY2022Q1	avtx	Class Of Stock Number Of Classes Of Stock Outstanding ClassOfStockNumberOfClassesOfStockOutstanding	2	class_of_stock
CY2022Q1	us-gaap	Weighted Average Number Of Shares Contingently Issuable WeightedAverageNumberOfSharesContingentlyIssuable	1676923	shares
CY2021Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.001
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	116000	USD
CY2021Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	95000	USD
CY2021Q1	avtx	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Exercised ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised	308880	shares
CY2022Q1	avtx	Lessee Operating Lease Number Of Leased Properties LesseeOperatingLeaseNumberOfLeasedProperties	2	property
CY2022Q1	avtx	Lessee Operating Lease Remaining Lease Team LesseeOperatingLeaseRemainingLeaseTeam	P6Y2M12D
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1940000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2001000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	522000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	485000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1945000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2018000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2467000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2503000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.092
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	391000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	528000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	537000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	547000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	557000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	258000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	426000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3244000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	777000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2467000	USD
CY2022Q1	avtx	Accrued Research And Development AccruedResearchAndDevelopment	5280000	USD
CY2021Q4	avtx	Accrued Research And Development AccruedResearchAndDevelopment	8221000	USD
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4780000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4310000	USD
CY2022Q1	avtx	Accrued General And Administrative Expenses AccruedGeneralAndAdministrativeExpenses	1108000	USD
CY2021Q4	avtx	Accrued General And Administrative Expenses AccruedGeneralAndAdministrativeExpenses	1275000	USD
CY2022Q1	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	92000	USD
CY2021Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	111000	USD
CY2022Q1	avtx	Commercial Operations Current CommercialOperationsCurrent	1910000	USD
CY2021Q4	avtx	Commercial Operations Current CommercialOperationsCurrent	1733000	USD
CY2022Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	440000	USD
CY2021Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	375000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	522000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	485000	USD
CY2022Q1	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	4000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	9000	USD
CY2022Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	14136000	USD
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	16519000	USD
CY2022Q1	avtx	Number Of Class Of Stock Authorized NumberOfClassOfStockAuthorized	2	class_of_stock
CY2022Q1	avtx	Capital Stock Shares Authorized CapitalStockSharesAuthorized	205000000	shares
CY2021Q1	avtx	Class Of Warrant Or Right Percent Ownership Threshold ClassOfWarrantOrRightPercentOwnershipThreshold	0.0999
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.001
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	4400000	USD
CY2021Q1	avtx	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Exercised ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised	308880	shares
CY2022Q1	avtx	Share Based Compensation Arrangement By Share Based Payment Award Share Reserve Increase As Percent ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent	0.04
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	2501823	shares
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5312000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1448000	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	0	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	0	shares
CY2021Q3	avtx	Debt Instrument Remaining Contingent Consideration Liability DebtInstrumentRemainingContingentConsiderationLiability	3000000	USD
CY2019Q3	avtx	Royalty Agreement Payment Received RoyaltyAgreementPaymentReceived	2000000	USD
CY2019Q3	avtx	Royalty Agreement Period After Public Launch To Terminate Agreement RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement	P3Y
CY2019Q3	avtx	Royalty Agreement Buyout Option Percentage Of Net Present Value Of Royalty Payments RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments	0.75

Files In Submission

Name	View Source	Status
0001628280-22-012436-index-headers.html	Edgar Link	pending
0001628280-22-012436-index.html	Edgar Link	pending
0001628280-22-012436.txt	Edgar Link	pending
0001628280-22-012436-xbrl.zip	Edgar Link	pending
avtx-20220331.htm	Edgar Link	pending
avtx-20220331.xsd	Edgar Link	pending
avtx-20220331_cal.xml	Edgar Link	unprocessable
avtx-20220331_def.xml	Edgar Link	unprocessable
avtx-20220331_g1.jpg	Edgar Link	pending
avtx-20220331_htm.xml	Edgar Link	completed
avtx-20220331_lab.xml	Edgar Link	unprocessable
avtx-20220331_pre.xml	Edgar Link	unprocessable
ex-312avtx1q2022.htm	Edgar Link	pending
ex-321avtx1q2022.htm	Edgar Link	pending
ex311avtx1q2022.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AVTX
Avalo Therapeutics, Inc. Stock $avtx

2022 Q2 Form 10-Q Financial Statement

#000162828022012436 Filed on May 05, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVTX Avalo Therapeutics, Inc. Stock $avtx

2022 Q2 Form 10-Q Financial Statement

#000162828022012436 Filed on May 05, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVTX
Avalo Therapeutics, Inc. Stock $avtx